Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EBITDA (2017 - 2025)

Historic EBITDA for Lexaria Bioscience (LEXX) over the last 12 years, with Q4 2025 value amounting to -$1.6 million.

  • Lexaria Bioscience's EBITDA rose 4086.35% to -$1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$10.8 million, marking a year-over-year decrease of 4762.64%. This contributed to the annual value of -$12.0 million for FY2025, which is 10553.79% down from last year.
  • As of Q4 2025, Lexaria Bioscience's EBITDA stood at -$1.6 million, which was up 4086.35% from -$2.7 million recorded in Q3 2025.
  • Lexaria Bioscience's 5-year EBITDA high stood at -$674537.0 for Q1 2024, and its period low was -$3.8 million during Q2 2025.
  • In the last 5 years, Lexaria Bioscience's EBITDA had a median value of -$1.8 million in 2024 and averaged -$1.9 million.
  • As far as peak fluctuations go, Lexaria Bioscience's EBITDA surged by 4803.78% in 2024, and later crashed by 31635.48% in 2025.
  • Over the past 5 years, Lexaria Bioscience's EBITDA (Quarter) stood at -$2.0 million in 2021, then rose by 12.36% to -$1.8 million in 2022, then skyrocketed by 33.09% to -$1.2 million in 2023, then plummeted by 130.38% to -$2.7 million in 2024, then skyrocketed by 40.86% to -$1.6 million in 2025.
  • Its EBITDA was -$1.6 million in Q4 2025, compared to -$2.7 million in Q3 2025 and -$3.8 million in Q2 2025.